Berwyn pharma firm gets approval for ALS drug
The Food and Drug Administration has approved ITF Pharma ’s new drug application for Tiglutik, a treatment for amyotrophic lateral sclerosis or ALS.
Tiglutik is, according to ITF Pharma, the first and only easy-to-swallow thickened riluzole liquid for ALS. The medicine is administered twice daily by oral syringe.
ALS, also known as Lou Gehrig’s dise ase, is a progressive and ultimately fatal neurodegenerative disease marked by a gradual degeneration of nerve cells of the central nervous system…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: ALS | Biotechnology | Brain | Food and Drug Administration (FDA) | Health Management | Neurology | New Drug Applications | Pharmaceuticals